Enact (ACT) Price, Holdings, & News

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enact in the last year. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" ACT shares.
View ACT analyst ratings or view top-rated stocks.

0 equities research analysts have issued 1-year target prices for Enact's shares. Their ACT share price targets range from $0.00 to $0.00. On average, they predict the company's share price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for ACT or view top-rated stocks among Wall Street analysts.

Enact's stock was trading at $28.89 at the beginning of the year. Since then, ACT stock has increased by 9.7% and is now trading at $31.70.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our ACT earnings forecast.

Enact Holdings, Inc. (NASDAQ:ACT) released its earnings results on Wednesday, May, 1st. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.05. The company had revenue of $291.58 million for the quarter, compared to the consensus estimate of $307.29 million. Enact had a trailing twelve-month return on equity of 14.68% and a net margin of 55.87%. During the same period in the previous year, the business earned $1.08 EPS.

Enact announced a quarterly dividend on Wednesday, May 1st. Stockholders of record on Wednesday, May 29th will be given a dividend of $0.185 per share on Thursday, June 13th. This represents a $0.74 dividend on an annualized basis and a dividend yield of 2.33%. The ex-dividend date is Wednesday, May 29th. This is a boost from the stock's previous quarterly dividend of $0.16.
Read our dividend analysis for ACT.

Enact is a equity fund issued by AdvisorShares. ACT focuses on theme investments. The fund's investments total to approximately $12.40 million assets under management.

Enact's management fee is 0.60% and has other expenses of 0.31%. However, ACT has a fee waiver of -0.16% to reimburse the expenses. The net expense ratio for ACT is 0.75%.

12 employees have rated Enact Chief Executive Officer Dave Page on Glassdoor.com. Dave Page has an approval rating of 100% among the company's employees. This puts Dave Page in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enact investors own include Cara Therapeutics (CARA), Cronos Group (CRON), Innovative Industrial Properties (IIPR), Amplify Alternative Harvest ETF (MJ), Organigram (OGI), Tilray (TLRY), Zynerba Pharmaceuticals (ZYNE) and

Enact (ACT) raised $253 million in an initial public offering (IPO) on Thursday, September 16th 2021. The company issued 13,310,400 shares at $19.00 per share.

Enact's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.98%), Edgestream Partners L.P. (0.12%), Denali Advisors LLC (0.11%), Foundry Partners LLC (0.09%), Sei Investments Co. (0.05%) and Russell Investments Group Ltd. (0.03%). Insiders that own company stock include Anne G Waleski, Brian Gould, Dominic James Addesso, Genworth Holdings, Inc, Hardin Dean Mitchell and Rohit Gupta.
View institutional ownership trends.

Shares of ACT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.